Susquehanna International Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-270,200
| Closed | -$1.13M | – | 13784 |
|
|
2023
Q1 | $1.13M | Buy |
270,200
+239,200
| +772% | +$1.24M | ﹤0.01% | 6481 |
|
|
2022
Q4 | $186K | Sell |
31,000
-581,200
| -95% | -$3.17M | ﹤0.01% | 10241 |
|
|
2022
Q3 | $3.56M | Buy |
612,200
+393,300
| +180% | +$2.45M | ﹤0.01% | 3744 |
|
|
2022
Q2 | $1.31M | Sell |
218,900
-90,700
| -29% | -$464K | ﹤0.01% | 5878 |
|
|
2022
Q1 | $1.45M | Buy |
309,600
+151,600
| +96% | +$452K | ﹤0.01% | 6225 |
|
|
2021
Q4 | $392K | Buy |
158,000
+81,600
| +107% | +$200K | ﹤0.01% | 9847 |
|
|
2021
Q3 | $225K | Sell |
76,400
-63,300
| -45% | -$172K | ﹤0.01% | 11228 |
|
|
2021
Q2 | $349K | Buy |
139,700
+25,800
| +23% | +$61.9K | ﹤0.01% | 10447 |
|
|
2021
Q1 | $331K | Buy |
113,900
+53,700
| +89% | +$175K | ﹤0.01% | 10394 |
|
|
2020
Q4 | $194K | Buy |
60,200
+8,100
| +16% | +$26.9K | ﹤0.01% | 10078 |
|
|
2020
Q3 | $112K | Buy |
+52,100
| New | +$66.5K | ﹤0.01% | 9858 |
|
|
2019
Q3 | – | Sell |
-52,700
| Closed | -$45K | – | 11312 |
|
|
2019
Q2 | $45K | Sell |
52,700
-7,200
| -12% | -$6.65K | ﹤0.01% | 9866 |
|
|
2019
Q1 | $58K | Buy |
+59,900
| New | +$63.1K | ﹤0.01% | 8439 |
|
|
2016
Q1 | – | Sell |
-17,370
| Closed | -$214K | – | 10410 |
|
|
2015
Q4 | $214K | Buy |
17,370
+170
| +1% | +$2.27K | ﹤0.01% | 8317 |
|
|
2015
Q3 | $251K | Buy |
17,200
+7,870
| +84% | +$136K | ﹤0.01% | 8337 |
|
|
2015
Q2 | $182K | Sell |
9,330
-10,080
| -52% | -$195K | ﹤0.01% | 9363 |
|
|
2015
Q1 | $351K | Buy |
19,410
+8,120
| +72% | +$183K | ﹤0.01% | 7702 |
|
|
2014
Q4 | $266K | Buy |
11,290
+7,120
| +171% | +$165K | ﹤0.01% | 8338 |
|
|
2014
Q3 | $101K | Sell |
4,170
-9,690
| -70% | -$252K | ﹤0.01% | 9069 |
|
|
2014
Q2 | $389K | Buy |
13,860
+6,050
| +77% | +$182K | ﹤0.01% | 7941 |
|
|
2014
Q1 | $266K | Sell |
7,810
-26,520
| -77% | -$906K | ﹤0.01% | 7786 |
|
|
2013
Q4 | $659K | Buy |
34,330
+28,310
| +470% | +$515K | ﹤0.01% | 6251 |
|
|
2013
Q3 | $99K | Sell |
6,020
-8,650
| -59% | -$100K | ﹤0.01% | 8089 |
|
|
2013
Q2 | $154K | Buy |
+14,670
| New | +$172K | ﹤0.01% | 7624 |
|
Other funds holding CTIC
Susquehanna International Group's CTIC Position: Q2 2023 in Review
Susquehanna International Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 813,905 shares — an estimated $3.42M sold.
Susquehanna International Group first reported a position in CTIC in Q2 2013 and held it in 26 quarters. The position peaked at $3.75M in Q3 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Susquehanna International Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Susquehanna International Group sold 813,905 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $3.42M.
- Susquehanna International Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 26 quarters.
- Susquehanna International Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $3.75M in Q3 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.